These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 9728983

  • 21. Effects of the Cessation of Mass Screening for Neuroblastoma at 6 Months of Age: A Population-Based Study in Osaka, Japan.
    Ioka A, Inoue M, Yoneda A, Nakamura T, Hara J, Hashii Y, Sakata N, Yamato K, Tsukuma H, Kawa K.
    J Epidemiol; 2016; 26(4):179-84. PubMed ID: 26548355
    [Abstract] [Full Text] [Related]

  • 22. [Neuroblastoma in the Rhone-Alpes area: epidemiologic data].
    Renaux P, Mathieu P, Chauvin F, Collet JP, Greffe J, Lacroix C, Narod S, Vocanson M, Ducos-Mieral C, Boschetti R.
    Pediatrie; 1990; 45(1):59-64. PubMed ID: 2158051
    [Abstract] [Full Text] [Related]

  • 23. Neuroblastoma screening data. An epidemiologic analysis.
    Goodman SN.
    Am J Dis Child; 1991 Dec; 145(12):1415-22. PubMed ID: 1669671
    [Abstract] [Full Text] [Related]

  • 24. A population-based study of neuroblastoma incidence, survival, and mortality in North America.
    Bernstein ML, Leclerc JM, Bunin G, Brisson L, Robison L, Shuster J, Byrne T, Gregory D, Hill G, Dougherty G.
    J Clin Oncol; 1992 Feb; 10(2):323-9. PubMed ID: 1732433
    [Abstract] [Full Text] [Related]

  • 25. Neuroblastomas in Denmark 1943-80. Epidemiological and clinical studies.
    Carlsen NL.
    Acta Paediatr Suppl; 1994 Oct; 403():1-27. PubMed ID: 7841631
    [Abstract] [Full Text] [Related]

  • 26. How frequent is spontaneous remission of neuroblastomas? Implications for screening.
    Carlsen NL.
    Br J Cancer; 1990 Mar; 61(3):441-6. PubMed ID: 2328213
    [Abstract] [Full Text] [Related]

  • 27. [Neuroblastoma in children: clinical and biological aspects. An experience of screening in France].
    Mathieu P, Favrot M, Frappaz D, Chauvin F, Greffe J, Montegue A, Lacroix C, David L, Brunat-Mentigny M, Philip T.
    Ann Biol Clin (Paris); 1993 Mar; 51(7-8):665-88. PubMed ID: 8166384
    [Abstract] [Full Text] [Related]

  • 28. Neuroblastoma Screening at 1 Year of Age: The Final Results of a Controlled Trial.
    Berthold F, Spix C, Erttmann R, Hero B, Michaelis J, Treuner J, Ernst A, Schilling FH.
    JNCI Cancer Spectr; 2021 Jul; 5(4):. PubMed ID: 34240006
    [Abstract] [Full Text] [Related]

  • 29. The burden of malignant melanoma--lessons to be learned from Austria.
    Monshi B, Vujic M, Kivaranovic D, Sesti A, Oberaigner W, Vujic I, Ortiz-Urda S, Posch C, Feichtinger H, Hackl M, Rappersberger K.
    Eur J Cancer; 2016 Mar; 56():45-53. PubMed ID: 26802530
    [Abstract] [Full Text] [Related]

  • 30. Lead-time and overdiagnosis estimation in neuroblastoma screening.
    Spix C, Michaelis J, Berthold F, Erttmann R, Sander J, Schilling FH.
    Stat Med; 2003 Sep 30; 22(18):2877-92. PubMed ID: 12953286
    [Abstract] [Full Text] [Related]

  • 31. Neuroblastoma: a 32-year population-based study--implications for screening.
    Huddart SN, Muir KR, Parkes S, Mann JR, Stevens MC, Raafat F.
    Med Pediatr Oncol; 1993 Sep 30; 21(2):96-102. PubMed ID: 8433685
    [Abstract] [Full Text] [Related]

  • 32. Neuroblastoma screening at one year of age.
    Schilling FH, Spix C, Berthold F, Erttmann R, Fehse N, Hero B, Klein G, Sander J, Schwarz K, Treuner J, Zorn U, Michaelis J.
    N Engl J Med; 2002 Apr 04; 346(14):1047-53. PubMed ID: 11932471
    [Abstract] [Full Text] [Related]

  • 33. Incidence and mortality of neuroblastoma in Canada compared with other childhood cancers.
    Gao RN, Levy IG, Woods WG, Coombs BA, Gaudette LA, Hill GB.
    Cancer Causes Control; 1997 Sep 04; 8(5):745-54. PubMed ID: 9328197
    [Abstract] [Full Text] [Related]

  • 34. [Neuroblastoma in the Auvergne region from 1986 to 1991: epidemiological data].
    Gembara P, Dechelotte P, Chazal J, Chauvin F, Chopard P, Goddon R, Goumy P, Masson A, Malpuech G, Deméocq F.
    Pediatrie; 1993 Sep 04; 48(11):801-4. PubMed ID: 8058441
    [Abstract] [Full Text] [Related]

  • 35. Population-based and controlled study to evaluate neuroblastoma screening at one year of age in Germany: interim results.
    Schilling FH, Berthold F, Erttmann R, Michaelis J, Spix C, Sander J, Schwarz K, Treuner J.
    Med Pediatr Oncol; 2000 Dec 04; 35(6):701-4. PubMed ID: 11107150
    [Abstract] [Full Text] [Related]

  • 36. Neuroblastoma trends in Osaka, Japan, and Great Britain 1970-1994, in relation to screening.
    Honjo S, Doran HE, Stiller CA, Ajiki W, Tsukuma H, Oshima A, Coleman MP.
    Int J Cancer; 2003 Feb 10; 103(4):538-43. PubMed ID: 12478672
    [Abstract] [Full Text] [Related]

  • 37. Patterns of childhood cancer incidence and mortality in Europe.
    Levi F, La Vecchia C, Lucchini F, Negri E, Boyle P.
    Eur J Cancer; 1992 Feb 10; 28A(12):2028-49. PubMed ID: 1419301
    [Abstract] [Full Text] [Related]

  • 38. Long-term survival of children with neuroblastoma prior to the neuroblastoma screening project in Germany.
    Burkhardt-Hammer T, Spix C, Brenner H, Kaatsch P, Berthold F, Hero B, Michaelis J.
    Med Pediatr Oncol; 2002 Sep 10; 39(3):156-62. PubMed ID: 12210443
    [Abstract] [Full Text] [Related]

  • 39. Lung involvement in neuroblastoma: incidence and characteristics.
    Cowie F, Corbett R, Pinkerton CR.
    Med Pediatr Oncol; 1997 Jun 10; 28(6):429-32. PubMed ID: 9143388
    [Abstract] [Full Text] [Related]

  • 40. Neuroblastoma mass screening: the arguments for and against.
    Treuner J, Schilling FH.
    Eur J Cancer; 1995 Jun 10; 31A(4):565-8. PubMed ID: 7576969
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.